ARTCLINE currently invests main resources into research and development. The company benefits from the long experiences of the team members and its close collaboration with partners. Main target is sepsis - a whole body inflammation associated with bacterial and fungal infection.
Sepsis is one of the major causes of death in the industrialized world, but exact knowledge about many aspects of the course of sepsis still is lacking. Therefore, ARTCLINE develops new technologies for both better diagnostic and therapy of severe infections. A new cell based diagnostic test and a cell based extracorporeal-treatment of sepsis have been invented and are transferred into products now.
Figures on the right:
scanning electron micrograph, Martin Sauer, 1998 (in cooperation with the Electron Micrograph Center at University of Rostock, Prof. Jonas)